These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23698061)

  • 1. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.
    Lamorde M; Byakika-Kibwika P; Mayito J; Nabukeera L; Ryan M; Hanpithakpong W; Lefèvre G; Back DJ; Khoo SH; Merry C
    AIDS; 2013 Mar; 27(6):961-965. PubMed ID: 23698061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
    J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study.
    Lefèvre G; Bhad P; Jain JP; Kalluri S; Cheng Y; Dave H; Stein DS
    Malar J; 2013 Sep; 12():312. PubMed ID: 24010572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
    Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
    PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
    Lefèvre G; Carpenter P; Souppart C; Schmidli H; McClean M; Stypinski D
    Br J Clin Pharmacol; 2002 Nov; 54(5):485-92. PubMed ID: 12445027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
    Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
    Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
    Mwesigwa J; Parikh S; McGee B; German P; Drysdale T; Kalyango JN; Clark TD; Dorsey G; Lindegardh N; Annerberg A; Rosenthal PJ; Kamya MR; Aweeka F
    Antimicrob Agents Chemother; 2010 Jan; 54(1):52-9. PubMed ID: 19841149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
    Green JA; Mohamed K; Goyal N; Bouhired S; Hussaini A; Jones SW; Koh GC; Kostov I; Taylor M; Wolstenholm A; Duparc S
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7321-7332. PubMed ID: 27697758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the pharmacokinetics of Coartem.
    Djimdé A; Lefèvre G
    Malar J; 2009 Oct; 8 Suppl 1(Suppl 1):S4. PubMed ID: 19818171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
    Tiono AB; Tinto H; Alao MJ; Meremikwu M; Tshefu A; Ogutu B; Ouedraogo A; Lingani M; Cousin M; Lefèvre G; Jain JP; Duparc S; Hamed K
    Malar J; 2015 Apr; 14():157. PubMed ID: 25886021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.
    Tarning J; Kloprogge F; Piola P; Dhorda M; Muwanga S; Turyakira E; Nuengchamnong N; Nosten F; Day NP; White NJ; Guerin PJ; Lindegardh N
    Malar J; 2012 Aug; 11():293. PubMed ID: 22913677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine.
    Ali S; Najmi MH; Tarning J; Lindegardh N
    Malar J; 2010 Oct; 9():275. PubMed ID: 20932349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Griffin S; Kose K; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5306-13. PubMed ID: 21876056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
    Nyunt MM; Nguyen VK; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Mwima MW; Achan J; Aweeka F; Parikh S; Mwebaza N
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1274-82. PubMed ID: 26666942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
    Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
    Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
    Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
    Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin.
    Olafuyi O; Coleman M; Badhan RKS
    Eur J Pharm Sci; 2017 Aug; 106():20-33. PubMed ID: 28546104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.